Meglumine antimoniate

Meglumine antimoniate
Systematic (IUPAC) name
	Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Identifiers
CAS Number	133-51-7
ATC code	P01CB01 (WHO) QP51AB01 (WHO)
PubChem	CID: 64953
ChemSpider	58479
ChEMBL	CHEMBL239129
NIAID ChemDB	008733
Chemical data
Formula	Variable
Molecular mass	Variable
	SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO ;
	InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 ; Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M ;
(what is this?) (verify)

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.^[1] It is manufactured by Aventis^[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

References

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.